Zai Lab to Participate in Investor Conferences in September 2025
ByAinvest
Thursday, Aug 28, 2025 7:34 am ET1min read
ZLAB--
At the Cantor Global Healthcare Conference, scheduled for Thursday, September 4, 2025, at 10:20 a.m. ET, members of Zai Lab's senior management team will deliver a presentation. The Morgan Stanley conference, set for Tuesday, September 9, 2025, at 2:35 p.m. ET, will feature a fireside chat with the company's leadership. Live webcasts of both events will be available on Zai Lab's Investor Relations page at ir.zailaboratory.com/webcasts-presentations, with archived replays accessible for up to 90 days following the events.
Zai Lab, based in China and the United States, is focused on discovering, developing, and commercializing innovative products that address unmet medical needs in oncology, immunology, neuroscience, and infectious disease. The company's portfolio includes several patented drug candidates, such as ZEJULA, OPTUNE, QINLOCK, NUZYRA, and VYVGART, among others.
This announcement follows Zai Lab's recent financial performance, where the company reported a narrowing loss in the first half of 2025, accompanied by a 15% increase in revenue [2].
References:
[1] https://www.stocktitan.net/news/ZLAB/zai-lab-announces-participation-in-investor-conferences-in-september-ujp2jo4end69.html
[2] https://www.marketscreener.com/news/zai-lab-s-loss-narrows-in-h1-as-revenue-jumps-15-ce7c50d8df88ff26
Zai Lab Limited will participate in investor conferences in September 2025, including the Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference. Members of the company's senior management team will present at the events, and live webcasts will be available on the company's website. The conferences will focus on the company's research-based biopharmaceutical products in areas such as oncology, immunology, neuroscience, and infectious disease.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a leading biopharmaceutical company, has announced its participation in two significant investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference, both taking place in New York, NY.At the Cantor Global Healthcare Conference, scheduled for Thursday, September 4, 2025, at 10:20 a.m. ET, members of Zai Lab's senior management team will deliver a presentation. The Morgan Stanley conference, set for Tuesday, September 9, 2025, at 2:35 p.m. ET, will feature a fireside chat with the company's leadership. Live webcasts of both events will be available on Zai Lab's Investor Relations page at ir.zailaboratory.com/webcasts-presentations, with archived replays accessible for up to 90 days following the events.
Zai Lab, based in China and the United States, is focused on discovering, developing, and commercializing innovative products that address unmet medical needs in oncology, immunology, neuroscience, and infectious disease. The company's portfolio includes several patented drug candidates, such as ZEJULA, OPTUNE, QINLOCK, NUZYRA, and VYVGART, among others.
This announcement follows Zai Lab's recent financial performance, where the company reported a narrowing loss in the first half of 2025, accompanied by a 15% increase in revenue [2].
References:
[1] https://www.stocktitan.net/news/ZLAB/zai-lab-announces-participation-in-investor-conferences-in-september-ujp2jo4end69.html
[2] https://www.marketscreener.com/news/zai-lab-s-loss-narrows-in-h1-as-revenue-jumps-15-ce7c50d8df88ff26
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet